Table 1 Baseline characteristics of the study cohort
Variables | All | Subjects with major adverse cardiovascular events | Subjects without major adverse cardiovascular events | P value |
|---|---|---|---|---|
n | 1140 | 192 | 948 | Â |
Age, years | 66 ± 11 | 70 ± 9 | 65 ± 11 |  < 0.001 |
Male | 859 (75) | 133 (69) | 726 (77) | 0.032 |
Current smoker | 182 (16) | 35 (18) | 147 (16) | 0.35 |
BMI, kg/m2 | 25.3 ± 3.6 | 25.3 ± 3.7 | 25.4 ± 3.6 | 0.71 |
T2DM | 402 (35) | 100 (52) | 302 (32) |  < 0.001 |
Hypertension | 827 (73) | 159 (83) | 668 (70) |  < 0.001 |
Prior history of MI | 83 (7) | 9 (5) | 74 (8) | 0.13 |
Antihypertensive medication | ||||
ACEI | 426 (37) | 62 (32) | 364 (38) | 0.11 |
ARB | 185 (16) | 36 (19) | 149 (16) | 0.30 |
Beta-blocker | 708 (62) | 103 (54) | 605 (64) | 0.008 |
CCB | 369 (32) | 62 (32) | 307 (32) | 0.98 |
Baseline SBP, mmHg | 130.0 ± 17.0 | 131.3 ± 18.6 | 129.8 ± 16.6 | 0.28 |
Baseline DBP, mmHg | 72.6 ± 10.8 | 69.4 ± 11.7 | 73.3 ± 10.5 |  < 0.001 |
Triglycerides, mmol/L | 1.49 ± 1.03 | 1.53 ± 0.96 | 1.49 ± 1.04 | 0.62 |
Total cholesterol, mmol/L | 4.07 ± 0.97 | 4.09 ± 1.04 | 4.07 ± 0.95 | 0.77 |
HDL cholesterol, mmol/L | 1.20 ± 0.33 | 1.17 ± 0.35 | 1.21 ± 0.33 | 0.17 |
LDL cholesterol, mmol/L | 2.16 ± 0.81 | 2.19 ± 0.88 | 2.16 ± 0.80 | 0.58 |
HbA1c, % | 6.59 ± 1.43 | 6.67 ± 1.41 | 6.58 ± 1.44 | 0.39 |
Clinic SBP | ||||
Mean, mmHg | 131.3 ± 11.6 | 133.4 ± 13.9 | 130.8 ± 11.1 | 0.004 |
SD | 13.6 ± 4.7 | 15.7 ± 5.5 | 13.2 ± 4.4 |  < 0.001 |
CV | 10.3 ± 3.4 | 11.8 ± 4.0 | 10.0 ± 3.2 |  < 0.001 |
ARV | 14.1 ± 4.9 | 16.1 ± 5.6 | 13.7 ± 4.6 |  < 0.001 |
Clinic DBP | ||||
Mean, mmHg | 72.4 ± 8.0 | 69.9 ± 7.8 | 73.0 ± 8.0 |  < 0.001 |
SD | 8.2 ± 2.5 | 8.9 ± 2.8 | 8.0 ± 2.4 |  < 0.001 |
CV | 11.4 ± 3.6 | 12.9 ± 4.1 | 11.1 ± 3.4 |  < 0.001 |
ARV | 8.5 ± 2.8 | 9.4 ± 3.0 | 8.3 ± 2.7 |  < 0.001 |